Targeting methionine addiction of cancer cells with methioninase
VS Pokrovsky, L Abo Qoura, EA Demidova, Q Han… - Biochemistry …, 2023 - Springer
All types of cancer cells are addicted to methionine, which is known as the Hoffman effect.
Restricting methionine inhibits the growth and proliferation of all tested types of cancer cells …
Restricting methionine inhibits the growth and proliferation of all tested types of cancer cells …
Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet
Y Kubota, Q Han, K Hamada, Y Aoki… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Rectal cancer is a recalcitrant disease with limited treatment options. Pre-
clinical studies have shown the efficacy of methionine restriction with a low-methionine diet …
clinical studies have shown the efficacy of methionine restriction with a low-methionine diet …
Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: a highly-rare case with long-term stable disease
Y Kubota, Q Han, C Hozumi, N Masaki… - Anticancer …, 2022 - ar.iiarjournals.org
Background: Pancreatic cancer is one of the most recalcitrant cancers, and more effective
therapy is needed. Pre-clinical studies have shown that patient-derived orthotopic xenograft …
therapy is needed. Pre-clinical studies have shown that patient-derived orthotopic xenograft …
Rapid reduction of CEA and stable metastasis in an NRAS-mutant rectal-cancer patient treated with FOLFIRI and bevacizumab combined with oral recombinant …
Y Kubota, Q Han, S Morinaga, T Tsunoda, RM Hoffman - in vivo, 2023 - iv.iiarjournals.org
Background/Aim: The choice of chemotherapy agents for RAS-mutant colorectal cancer is
limited, and prognosis is poor compared to RAS-wild-type colorectal cancer. The purpose of …
limited, and prognosis is poor compared to RAS-wild-type colorectal cancer. The purpose of …
Oncogenes and methionine addiction of cancer: Role of c-MYC
Y Aoki, Q Han, Y Kubota, N Masaki… - Cancer genomics & …, 2023 - cgp.iiarjournals.org
Abstract Background/Aim: Methionine addiction is a general and fundamental hallmark of
cancer cells, termed the Hoffman effect. Previously Vanhamme and Szpirer showed that …
cancer cells, termed the Hoffman effect. Previously Vanhamme and Szpirer showed that …
Recombinant methioninase decreased the effective dose of irinotecan by 15-fold against colon cancer cells: a strategy for effective low-toxicity treatment of colon …
M Sato, Q Han, Y Kubota, A Baranov… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Irinotecan (IRN), a topoisomerase I inhibitor and pro-drug of SN-38, is first-
line treatment of colon cancer as part of FOLFIRI and FOLFOXIRI combination …
line treatment of colon cancer as part of FOLFIRI and FOLFOXIRI combination …
[HTML][HTML] Efficacy of recombinant methioninase on late-stage patient cancer in the histoculture drug response assay (HDRA) as a potential functional biomarker of …
Y Kubota, M Sasaki, Q Han, C Hozumi… - Cancer Diagnosis & …, 2024 - ncbi.nlm.nih.gov
Results Colorectal cancer and pseudomyxoma had the highest sensitivity to rMETase.
Pancreatic and ovarian cancer also responded to rMETase, but to a lesser degree …
Pancreatic and ovarian cancer also responded to rMETase, but to a lesser degree …
[11C] Methionine-PET imaging as a cancer biomarker for methionine addiction and sensitivity to methionine-restriction-based combination chemotherapy
Y Kubota, T Sato, Q Han, C Hozumi, S Morinaga… - in vivo, 2024 - iv.iiarjournals.org
Background/Aim: Methionine addiction is a fundamental and universal hallmark of cancer,
termed the Hoffman effect. Methionine addiction of cancer is greater than glucose addiction …
termed the Hoffman effect. Methionine addiction of cancer is greater than glucose addiction …
Recombinant oral methioninase (o-rMETase) combined with oxaliplatinum plus 5-fluorouracil improves survival of mice with massive colon-cancer peritoneal …
MJ Kim, Q Han, M Bouvet, RM Hoffman… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: The present study aimed to determine if oral methioninase (o-rMETase)
combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with …
combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with …
Oral-recombinant methioninase lowers the effective dose and eliminates toxicity of cisplatinum for primary osteosarcoma of the mammary gland in a patient-derived …
N Masaki, Q Han, NF Wu, C Samonte, J Wu, C Hozumi… - in vivo, 2022 - iv.iiarjournals.org
Abstract Background/Aim: Primary osteosarcoma of the mammary gland is a very rare
disease, accounting for under 1% of all mammary gland malignancies. There is no …
disease, accounting for under 1% of all mammary gland malignancies. There is no …